US 10815266
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted A61KA61K31/7076A61P
Quick answer
US patent 10815266 (β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment) held by Atea Pharmaceuticals, Inc. expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Atea Pharmaceuticals, Inc.
- Grant date
- Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 2
- CPC classes
- A61K, A61K31/7076, A61P, A61P31/14